Medical Dialogues’ Post

Edwards Lifesciences has officially completed the sale of its Critical Care business to BD for a staggering $4.2 billion. This change represents a significant move within the industry, impacting both companies and their future directions. Operating as an independent unit within BD's Medical segment, Critical Care will continue its operations from Irvine, California. Katie Szyman, who played a pivotal role at Edwards, will continue to lead the unit. The funds from this sale are earmarked for strategic initiatives at Edwards, including recent acquisitions and share repurchases. Notably, Edwards has been active in the market, recently securing several high-profile acquisitions such as Innovalve Bio Medical Ltd., JenaValve Technology, Inc., and Endotronix. Edwards CEO Bernard Zovighian highlighted the importance of this sale, tying it to the company's focused ambition in structural heart innovation. This shift allows Edwards to hone in on its core areas like TAVR and TMTT while expanding its influence in surgical leadership and new heart therapies. #MedTech #HealthcareInnovation #BusinessGrowth

J&J's Strategic Medtech Acquisitions Johnson & Johnson (J&J) is making notable strides in the medtech sector, reflected by a Q3 medtech sales of $7.89 billion, a 5.8% year-over-year increase. The cardiovascular group stood out with over 26% growth, significantly boosted by the acquisitions of Abiomed and Shockwave Medical. These two alone added nearly $2 billion to Q3 sales, with Abiomed contributing $362 million, a 16.3% year-over-year growth. These moves mark J&J's shift towards higher-growth, higher-margin categories. The recent $1.6 billion acquisition of V-Wave supports this strategy, strengthening their cardiovascular portfolio and balancing slower growth in other areas. J&J's CEO, Joaquin Duato, highlighted ongoing innovation efforts like the submission of an investigational device exemption application for the Ottava surgical robot. #MedTech #JohnsonAndJohnson #CardiovascularBusiness

Baxter Becomes a Global MedTech Leader with Hillrom Acquisition United States: Baxter International Inc., a leading healthcare company, has successfully acquired medical equipment manufacturer Hillrom Holdings, solidifying its position as a global MedTech leader with a valuation of USD 15 billion. This acquisition aligns with Baxter's goal to transform healthcare and improve patient care worldwide by fostering innovation and enhancing efficiency across various care settings. Additionally, Baxter plans to expand its global presence by making Hillrom and Welch Allyn products more accessible to patients and caregivers in new international markets, supported by a strong commercial and service infrastructure. The acquisition positions Baxter for accelerated growth, both in revenue and profitability. #BaxterInternational, #HillromAcquisition, #MedTechLeader, #HealthcareInnovation, #GlobalHealthcare, #PatientCare, #MedTech, #BaxterGrowth, #HealthcareTransformation, #GlobalExpansion, #MedicalEquipment, #WelchAllyn, #InnovationInHealthcare, #BusinessAcquisition, #TopLineGrowth

𝐅𝐨𝐫𝐭𝐢𝐬 𝐬𝐭𝐫𝐞𝐧𝐠𝐭𝐡𝐞𝐧𝐬 𝐢𝐭𝐬 𝐟𝐨𝐨𝐭𝐡𝐨𝐥𝐝 𝐢𝐧 𝐝𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜𝐬! Fortis Healthcare has applied for CCI approval to increase its stake in Agilus Diagnostics by 31.52%, #acquiring shares worth ₹1,780 Cr from three private equity firms. 📊 This move will raise Fortis's stake to 89.2%, with Agilus valued at ₹5,700 Cr. Specializing in 3,600+ tests, Agilus is a key player in #India’s diagnostics sector, and this #acquisition will strengthen Fortis’s #foothold. Fortis assures that the deal will not adversely affect market competition. 🔬 🔗Read More - https://lnkd.in/ddt5Jsst 🖊️Written By - Dr. Aishwarya D Sarthe 🌐Stay Informed with our Latest Stories – https://lnkd.in/gMUPB2Zp #Diagnostics #Healthcare #FortisHealthcare #Investments #CCI #HealthInnovation #MergersAndAcquisitions #TechInHealthcare

Merit Medical Systems, Inc. has announced its latest strategic move by acquiring Cook Medical’s lead management device portfolio for $210 million. This significant acquisition underscores Merit’s commitment to expanding its offerings and enhancing its support for cardiac intervention patients. The deal is expected to close in Q4 2024, with Merit Medical leveraging cash reserves and long-term credit for the purchase. CEO Fred P. Lampropoulos highlighted that this acquisition aligns with Merit’s growth strategy and will enable the company to offer a more comprehensive range of solutions from diagnosis to post-procedure care. Cook Medical’s lead management portfolio, which has generated $37 million in revenue in 2023, is a valuable addition. The portfolio has a strong presence in the U.S. and EMEA regions. The transaction is pending antitrust approval but includes a transition agreement with Cook Medical for continued support over the next two years. In addition to this acquisition, Merit Medical recently acquired the rights to the EsophyX Z+ device from EndoGastric Solutions for $105 million. #MedTech #HealthcareInnovation #Acquisition #MeritMedical #InterventionalRadiology #CardiacCare

🌟 𝗧𝗼𝗽 𝗠𝗲𝗱𝗧𝗲𝗰𝗵 𝗗𝗲𝗮𝗹𝘀 𝗼𝗳 𝟮𝟬𝟮𝟰: 𝗔 𝗚𝗮𝗺𝗲-𝗖𝗵𝗮𝗻𝗴𝗲𝗿 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗜𝗻𝗱𝘂𝘀𝘁𝗿𝘆 🌟🔬📣 The first half of 2024 has been monumental for the MedTech industry, with several high-impact deals reshaping the landscape. 🚀🔬 Here are some of the standout transactions: 💰𝗝𝗼𝗵𝗻𝘀𝗼𝗻 & 𝗝𝗼𝗵𝗻𝘀𝗼𝗻'𝘀 $𝟭𝟯.𝟭𝗕 𝗔𝗰𝗾𝘂𝗶𝘀𝗶𝘁𝗶𝗼𝗻 𝗼𝗳 𝗦𝗵𝗼𝗰𝗸𝘄𝗮𝘃𝗲 𝗠𝗲𝗱𝗶𝗰𝗮𝗹: This deal highlights J&J’s commitment to expanding its cardiovascular portfolio and bringing advanced technologies to market. 💰𝗕𝗼𝘀𝘁𝗼𝗻 𝗦𝗰𝗶𝗲𝗻𝘁𝗶𝗳𝗶𝗰'𝘀 $𝟯.𝟳𝗕 𝗣𝘂𝗿𝗰𝗵𝗮𝘀𝗲 𝗼𝗳 𝗔𝘅𝗼𝗻𝗶𝗰𝘀: A strategic move to strengthen its position in the neuromodulation space. 💰𝐁𝐃'𝐬 𝐀𝐜𝐪𝐮𝐢𝐬𝐢𝐭𝐢𝐨𝐧 𝐒𝐩𝐫𝐞𝐞: BD continues to bolster its portfolio with targeted acquisitions, enhancing its market presence and capabilities. These deals reflect the ongoing innovation and growth within the MedTech sector, driving forward advancements in patient care and medical technology. Johnson & Johnson Boston Scientific BD https://lnkd.in/dAii4vf8 #MedTech #HealthcareInnovation #IndustryNews #JohnsonAndJohnson #BostonScientific #BD #MergersAndAcquisitions

Medline Industries, LP Targets Over $5 Billion in 2025 IPO Medline Industries, a leading medical supply company, plans to raise more than $5 billion through an initial public offering (IPO) in 2025, aiming for a valuation around $50 billion. The #IPO could occur as early as the second quarter. Owned by private equity firms Blackstone, The Carlyle Group, and Hellman & Friedman, Medline Industries, LP has invited investment banks to vie for lead roles in the offering. This move aligns with other major firms preparing for public listings following a period of market instability. Medline, acquired for $34 billion in 2021, operates in over 100 countries with annual sales exceeding $23 billion. This significant IPO reflects Medline's robust position in the medical supply sector and indicates a resurgence in public offerings within the industry. #MedTech #HealthcareInnovation #IPO #MedicalDevices #HealthcareInvestment #PEBacked #MedlineIndustries #LifeSciences #GrowthStrategy #IndustryNews

Shockwave is in Takeover Talks In December, DKI recommended Shockwave Medical $SWAV at $190. The thesis was the company was growing quickly due to an unchallenged best-in-class product enabling stent placement in cases that were difficult due to excessive calcification of an artery. We further said that the company was a takeover target and we expected it would be acquired for more than $300 a share. Potential takeover suitors mentioned included Johnson & Johnson $JNJ, Boston Scientific $BSX, and Medtronic $MDT. Today the Wall Street Journal reported that Shockwave is in acquisition talks with Johnson & Johnson. The stock closed at $323, up 69% in the approximately four months since DKI recommended $SWAV. The report mentions the possibility of a second suitor entering the bidding. Boston Scientific offered $285 a share for Shockwave less than a year ago so it will be interesting to see if they return for another attempt to buy the company. A round of applause for Dr. Paul Thompson, Cardiologist and member of the DKI Board of Advisors, who suggested the idea to me. A second round of applause for Interventional Cardiologist, Dan Fram, who explained why Shockwave’s product was the best possible option for difficult cases and helped me understand how he uses their devices. We did a subscribers-only webinar with them in January to explain the technology and the investment case. That video is available to subscribers on the DKI website.

Shockwave is in Takeover Talks In December, DKI recommended Shockwave Medical $SWAV at $190. The thesis was the company was growing quickly due to an unchallenged best-in-class product enabling stent placement in cases that were difficult due to excessive calcification of an artery. We further said that the company was a takeover target and we expected it would be acquired for more than $300 a share. Potential takeover suitors mentioned included Johnson & Johnson $JNJ, Boston Scientific $BSX, and Medtronic $MDT. Today the Wall Street Journal reported that Shockwave is in acquisition talks with Johnson & Johnson. The stock closed at $323, up 69% in the approximately four months since DKI recommended $SWAV. The report mentions the possibility of a second suitor entering the bidding. Boston Scientific offered $285 a share for Shockwave less than a year ago so it will be interesting to see if they return for another attempt to buy the company. A round of applause for Dr. Paul Thompson, Cardiologist and member of the DKI Board of Advisors, who suggested the idea to me. A second round of applause for Interventional Cardiologist, Dan Fram, who explained why Shockwave’s product was the best possible option for difficult cases and helped me understand how he uses their devices. We did a subscribers-only webinar with them in January to explain the technology and the investment case. That video is available to subscribers on the DKI website.

Johnson & Johnson Concludes Acquisition Of Shockwave Medical Johnson & Johnson has announced it has completed its acquisition of Shockwave Medical. Shockwave is now part of Johnson & Johnson and will operate as a business unit within Johnson & Johnson MedTech. Shockwave is ultimately expected to become Johnson & Johnson MedTech’s thirteenth priority platform, as defined by annual sales of at least $1 billion. The transaction is expected to accelerate revenue growth for both Johnson & Johnson and Johnson & Johnson MedTech. Johnson & Johnson expects the transaction to be accretive to operating margin, but considering the impact of financing costs, is expected to dilute adjusted earnings per share by approximately $0.10 in 2024 and approximately $0.17 in 2025. In connection with the completion of the transaction, Shockwave’s common stock ceased trading on NASDAQ. Joaquin Duato Tim Schmid #johnsonandjohnson #johnsonandjohnsonnews #acquisition #shockwavemedical